89bio, Inc.
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
ETNB | US
Overview
Corporate Details
- ISIN(s):
- US2825591033
- LEI:
- Country:
- United States of America
- Address:
- 655 MONTGOMERY STREET, 94111 SAN FRANCISCO
- Website:
- https://www.89bio.com/
- Sector:
- Manufacturing
Description
89bio, Inc. is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic diseases. The company's lead product candidate, pegozafermin, is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company focuses on creating innovative and potentially best-in-class treatments to address unmet medical needs in its target patient populations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all 89bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for 89bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for 89bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
